Pfizer's New Drug Revenue Surges 32% in Q3 2026 Amidst Patent Cliff Concerns
Trendline

Pfizer's New Drug Revenue Surges 32% in Q3 2026 Amidst Patent Cliff Concerns

What's Happening? Pfizer (NYSE:PFE) reported a 32% increase in revenue from its recently launched and acquired products during the third quarter of 2026. This growth is seen as a significant step in addressing the company's impending 'patent cliff,' a period where key drug patents expire, leading to
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.